Dementia testing specialist boosted with six-figure investment

A fast-growing company that specialises in the genetic testing for Alzheimer’s disease has secured a six figure investment to boost its growth plans.

Maven Capital Partners, one of the UK’s most active SME finance providers, has invested an undisclosed sum on behalf of NPIF–Maven Equity Finance, part of the Northern Powerhouse Investment Fund (NPIF).

Cytox, which has offices in Manchester and Oxford, has a mission to transform how treatments are developed, people are screened and therapies are prescribed for neurological diseases, including Alzheimer’s disease.

Alzheimer’s is expected to impact more than 131 million people by 2050 and Cytox’s genetic prognostic test predicts the risk of someone developing the disease years before the first signs become apparent.

The tests are based on the academic work of Dr Zuszanna Nagy at the University of Birmingham and formerly at University of Oxford, and Prof John Hardy at University College London.

The business is now looking to boost its growth plans in the UK and overseas and has secured an undisclosed six figure investment from NPIF-Maven Equity Finance.

In addition to Maven, the investment was also supported by the GM&C Life Sciences Fund, Perivoli Innovations, Oxford Technology and Innovations EIS Fund.